What’s New

ARVO: Isarna’s abstract "Efficacy of ISTH0036, a Potent and Selective Antisense Oligonucleotide Targeting Transforming Growth Factor beta 2 (TGF-β2) Isoform, in Different Ocular Disease Preclinical Models" has been selected for oral presentation at the 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), May 3-7 in Denver, Colorado, USA. The data will be presented by Dr. Michel Janicot, Isarna Head of Preclinical Research and Development.
Two additional abstracts covering the preclinical profile of Isarna's ISTH0036 were accepted for poster presentations during the meeting. The posters will be made available on our website at the time of presentation.